Company ProfilePremium

China Starch Holdings Limited

Company Profile Analysis

Ticker: 3838.HK中國澱粉控股有限公司

ESOMAR 23 Corporate BadgeISO Certifications Badge
China Starch Holdings Limited - Company showcase

Year Founded & Workforce

2006

2,177 Employees

China Starch Holdings Limited logo

China Starch Holdings Limited Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

China Starch Holdings Limited Overview

MetricFY2024FY2025H1 2026
Full-time staff (period end)2,2092,2012,177
Total staff costs incl. directors (RMB M)283.7301.3162.2

China Starch Holdings is a mid-sized, vertically integrated corn wet-miller and fermentation producer based in Shandong. It converts about 3–4 million tonnes of corn kernel a year into native cornstarch, by-products, and value-added derivatives. Its main derivatives are feed-grade lysine, starch-based sweeteners, modified starch and an emerging biobased-materials line (lactic acid and lactide/PLA trial lines). Revenue was RMB10.06bn in FY2025.

Two-thirds of revenue comes from commoditised upstream starch at low single-digit gross margins. Most profit comes from fermented products, chiefly lysine, which depends on the hog cycle and is now hit by EU, U.S. and other anti-dumping regimes.

The group's distinguishing traits are a net-cash balance sheet, about 34% insider control, a long history of uninterrupted final dividends, and a capital-light record. It is spending about RMB1.05bn on a Linqing cornstarch rebuild and an on-site thermal power plant to lower unit costs in an industry consolidating around scale. It swung to a first-half loss in H1 2026.


Company's own description (Annual Report 2025, Directors' Report)

The Company is an investment holding company. Its subsidiaries are principally engaged in the manufacture and sale of cornstarch, lysine, starch-based sweetener, modified starch and ancillary corn-based and corn-refined products. Revenue comes from two business segments, (i) upstream products and (ii) fermented and downstream products. All production is carried out in the PRC.

Independent characterisation

China Starch is a classic corn-refining "spread business." It buys corn kernel on the spot market and has not hedged in any year from FY2021 to H1 2026. Corn kernel and utilities make up about 97% of cost of sales (FY2025: cost of inventories RMB8,196m plus utilities RMB1,012m, against total cost of sales of RMB9,518m). Margins are therefore set by the spread between corn and the realised price of starch, lysine and co-products, not by pricing power.

The value chain is integrated:

  1. Wet milling. Corn is steeped and milled into starch and co-products: corn gluten meal, corn germ, corn fibre/bran and corn steep liquor.

  2. Captive feedstock. Part of the starch moves inter-segment into fermentation and conversion. Inter-segment sales were RMB2,006m in FY2025, up from RMB220m in FY2021. That rise reflects the 2023 lysine capacity expansion, which now consumes a much larger share of captive starch.

  3. Fermentation and conversion. Captive starch becomes lysine (feed amino acid), liquid and crystallised starch sweeteners (glucose and maltose syrups), modified starches, and lactic acid and biobased materials.

Revenue model. The business is 100% product sales, recognised at a point in time (FY2025 note 2). There is no service, subscription or licensing revenue. Contracts are short (under one year). Customer credit runs 0–150 days, but receivables are tiny: 13 debtor days in FY2025, and most are bank acceptance bills.

Customer types and end-markets:

Animal feed: Lysine, corn gluten meal, corn fibre and germ meal. This is the largest profit pool and follows the PRC hog cycle.

Food and beverage: Native and modified starch, liquid sweeteners for drinks, confectionery and baking.

Industrial: Paper, textile, chemical, fermentation and pharmaceutical customers. Management has also targeted battery manufacturing as a new outlet for starch sugars (FY2023 MD&A).

Biobased materials: Lactic acid and lactide/PLA for biodegradable plastics. This is a niche and still sub-scale.

Export: 4.5% of FY2025 revenue (RMB449m), mostly lysine and cornstarch. Export share is shrinking under trade remedies.

Value-chain position. The group sits midstream: between grain growers and traders upstream, and feed mills, food and beverage manufacturers and industrial users downstream. It has no branded consumer business. Its competitive levers are scale, energy cost (steam and electricity), yield and logistics. The Linqing thermal power plant is a direct play on the energy lever.

Strategy

Stated strategy themes (management's words paraphrased; FY2025 and H1 2026 MD&A)

  1. Scale and cost leadership in a consolidating industry. Management expects players who fail to expand capacity and adopt advanced technology to lose share gradually. It sees this consolidation continuing for the foreseeable future.

  2. Expand the domestic distribution network and use economies of scale. This is reinforced in H1 2026 by redirecting lysine and sweetener sales to domestic customers.

  3. Efficiency enhancement and cost optimisation in a low-margin, oversupplied environment (H1 2026 priority #1).

  4. Prudent capital allocation. Stay cautious on future expansion and avoid products subject to capacity gluts (H1 2026 priority #2). This is a notable pivot from the 2022–2023 growth agenda (lysine, PLA, JV).

  5. Shareholder returns via buybacks. Management states the 154m-share repurchase aims to lift EPS once the market recovers.

  6. Energy self-sufficiency. The on-site thermal power plant at Linqing is meant to stabilise steam and electricity supply and cut cost.

Initiative register (last 24 months)

InitiativeAnnouncedInvestmentFundingTarget / status
Linqing Cornstarch Production Project (demolish and rebuild; 1.0Mt to 1.55Mt)20 Feb 2025RMB620mInternal resourcesOriginal target: operational June 2026. Revised: trial operation by end-2026 (H1 2026).
Linqing Thermal Power Project (dual-boiler, high-efficiency turbine generator)20 Feb 2025RMB428.7mInternal resources and bank borrowingsConstruction about 30 Jan 2026 to 31 Mar 2027. Commissioning Q1 2027.
Construction contract (facilities) with Juneng Construction25 May 2025RMB80mInternalApproved at EGM 9 Oct 2025 (99.99%)
Thermal plant construction contract with Juneng Construction19 Nov 2025RMB70m (after a 14% rebate)InternalConnected transaction requiring independent shareholder approval.
Lactic acid esters JV (Musashino)Initiated 2020Budget n/d—Land acquired Feb 2026. Under feasibility reappraisal (Aug 2026).
Share buyback programme2,026About HK$25.96m (154m shares)CashDone; shares cancelled 3 Aug 2026
Biobased materials channel expansion2,026—OpexVolume up YoY in H1 2026; margins down

Medium-term financial targets: none disclosed. The company does not publish guidance.

ESG commitments: no quantified targets in the sources retrieved.

Products & Services

No product is sold under a disclosed consumer brand. Products are sold as specification-grade commodities. Pricing is spot or short-contract and is not published beyond the realised ASPs below.

Installed capacity (end-2023, FY2023 Results — latest full table disclosed)

ProductAnnual capacity (tonnes)
Cornstarch2,700,000
Lysine500,000
Starch-based sweetener (crystallised)150,000
Modified starch100,000
D-lactic acid20,000
Lactide / polylactide trial lines5,000 each (planned; trial use, excluded from the table above)

Post-project: the Linqing cornstarch line is being rebuilt from 1.0Mt to 1.55Mt, with trial operation expected by end-2026. That implies group cornstarch capacity of about 3.25Mt (derived, assuming no other changes).

Upstream products segment

ProductDescription and specificationTarget customerNotes
Native cornstarchCore wet-milled product; flagship by volumeFood processors, paper, textile, pharma, fermentation and chemical industriesVolume 1,698,626t in FY2025; ASP RMB2,472/t
Corn gluten mealHigh-protein feed ingredient from wet millingFeed millsPrice linked to soybean meal (FY2022 MD&A)
Corn germOil-bearing germ for corn oil crushingEdible oil crushersPrice linked to soybean oil (FY2022 MD&A)
Corn fibre / branFibre feed ingredientFeed millsDemand tied to the breeding cycle
Corn steep liquor (slurry)Nutrient-rich steep waterFermentation and feedVolumes and prices n/d

Fermented and downstream products segment

ProductDescription and specificationTarget customerLatest data
LysineEssential amino acid feed additive; the group offers "different purity grades" as a one-stop lysine supplier (FY2022 MD&A). Grade split n/d.Feed compounders (swine and poultry), domestic and exportFY2025 volume 561,447t; derived ASP about RMB5,206/t. H1 2026: 299,605t at RMB4,607/t.
Starch-based sweetener (liquid)Glucose and maltose syrups; less energy-intensive than crystallised, as no crystallisation step is neededBeverage, confectionery, food; trial outreach to battery manufacturing (FY2023)77.8% of sweetener volume in FY2025
Starch-based sweetener (crystallised)Crystalline dextrose/glucose; capacity 150ktFood, pharma22.2% of sweetener volume in FY2025
Modified starchChemically or physically modified starches, including "liquid modified starch," developed to get around dehydration and sewage constraints (FY2023)Paper, food, textileFY2025 volume 64,573t (FY2024: 113,023t). Output limited by sewage-control measures.
Biobased materials (D-lactic acid)20,000 tpa line; trial run 2022, normal operation Dec 2022Biodegradable plastics, chemicalsIncluded in "Others": RMB166.6m in FY2025
Lactide / PLA (trial)Trial lines completed end-2023 for product developmentBioplasticsCommercial output n/d
Lactic acid esters (JV, planned)Shouguang Juneng Musashino Biotechnology with Musashino Chemical Laboratory. Original 2022 target: 20,000 tpa by end-2024.Solvents and chemicalsLand bought Feb 2026; project "under further appraisal" (H1 2026)
Other (per aggregator profiles)Dextrin, food-grade enzymes, food additivesFood industry—

Volume and realised price history

MetricFY2021FY2022FY2023FY2024FY2025
Cornstarch sales volume (tonnes)1,915,7941,953,5632,007,2041,840,1481,698,626
Cornstarch ASP (RMB per tonne)2,9882,8722,8162,6262,472
Lysine sales volume (tonnes)320,638314,179340,746578,095561,447
Lysine ASP (RMB per tonne; FY2024–25 derived)6,9377,7186,6385,9295,206
Sweetener sales volume (tonnes)196,049237,718179,598217,581216,978
Sweetener ASP (RMB per tonne)2,6502,2772,6292,3012,046
Average corn kernel cost (RMB per tonne, net of VAT)2,5422,5502,5432,0712,082
Liquid sweetener share of sweetener volume (%)69.472.9—76.677.8

Note: The FY2023 liquid sweetener share is n/d. Modified starch volume is disclosed only for FY2024 (113,023t) and FY2025 (64,573t).

H1 2026 corn cost: RMB2,175/t (H1 2025: RMB2,068/t).

Financial Narrative

All figures are RMB millions from audited annual results announcements unless noted. EBITDA is derived as reported operating profit plus D&A.

Income statement

There are no dilutive instruments: no share options have been granted under the Share Option Scheme (FY2025).

Margins and growth (derived)

Revenue CAGR (derived): FY2021–FY2025 is −3.6% a year. FY2020–FY2025, from RMB8,892.3m, is +2.5% a year.

Balance sheet (31 December)

Notes:

  • The FY2025 intangible asset of RMB75.5m is a newly recognised item. Cash flow shows RMB24.4m spent on intangibles, and a prepayment for a construction project of RMB47.2m was reclassified. Its nature is not described in the extracts reviewed.

  • Long-term borrowings in FY2024–25 are a HK$-denominated loan from the controlling shareholder at a fixed 0.5% p.a. (RMB60.5m at FY2025). In FY2022–23 the shareholder loan sat within current borrowings at a floating rate.

  • All bank borrowings are short-term, RMB-denominated and fixed-rate.

H1 2026: total assets RMB7,121.9m; cash RMB1,986.8m; pledged deposits RMB478.5m; borrowings RMB1,282.3m (current RMB1,158.5m, non-current RMB123.8m); total equity RMB4,534.5m.

Cash flow

Notes:

  • Dividends paid in the S&P data exceed the company's dividends to owners (FY2022: RMB34.9m to owners vs RMB138.4m total). The difference is very likely dividends to non-controlling interests at non-wholly-owned subsidiaries.

  • The company's FY2024 results announcement records no buyback in FY2024. The S&P figure of RMB0.55m may reflect settlement timing of late-2023 trades.

Ratios

Ratio methodology:

  • FY2021 ROE, ROA and asset turnover use year-end balances.

  • ROIC = operating profit × (1 − 25%) ÷ (total equity + borrowings − cash), at year-end.

  • Turnover days, current and quick ratios, gearing and TSR are company-reported.

Commentary on trends, inflections and drivers

Revenue. Revenue peaked at RMB11.95bn in FY2022 and has fallen for three straight years, to RMB10.06bn in FY2025. Volume did not drive most of this decline. Cornstarch ASP fell 17% from RMB2,988/t (FY2021) to RMB2,472/t (FY2025). Lysine ASP fell about 33% from its RMB7,718/t peak in FY2022 to about RMB5,206/t in FY2025, and dropped further to RMB4,607/t in H1 2026.

Lysine volume grew about 70% in FY2024 after the capacity expansion, but this only partly offset price compression. The FY2025 decline also reflects a deliberate capacity cut: one Linqing cornstarch line was demolished for the rebuild, and cornstarch volume fell 7.7%.

Profitability is a corn-spread story. FY2024's record attributable profit of RMB482.3m came from a 19% drop in corn cost, from RMB2,543/t to RMB2,071/t, which management itself called unsustainable. FY2025 corn cost was roughly flat at RMB2,082/t, but product prices fell. Gross margin halved to 5.4%.

In H1 2026, corn rose 5.2% to RMB2,175/t while lysine ASP fell 18.4%. Gross margin compressed to 2.7% and the operating result turned to a loss of RMB55.4m. Without hedging, the group has full earnings exposure to the corn basis.

R&D collapse. Research expenses fell 86% from RMB324.1m (FY2022) to RMB46.8m (FY2025). Management attributes this to fewer projects. Part of the FY2024 profit recovery is therefore lower discretionary spending, not just better spreads.

Other income quality. Amortisation of government grants contributed RMB62.9m–RMB81.8m a year in FY2021–FY2025. It fell to RMB6.7m in H1 2026 because certain grants were fully amortised in 2025. This is a structural loss of about RMB60–70m in annual pre-tax income from FY2026.

Balance sheet and cash. The group has been net cash every year. Gross borrowings rose sharply in FY2024 to RMB1.48bn, alongside pledged deposits of RMB1.16bn. This is consistent with bill and deposit arbitrage: borrowing short-term at low fixed rates against pledged deposits, which explains rising finance income (RMB49.3m in FY2025). True economic leverage is negligible.

Free cash flow is volatile and working-capital driven. It was negative in FY2023 and FY2025. Capex is rising with the RMB1.05bn Linqing programme.

Returns. ROE averaged about 8% over five years but swings from 3% to 12% with the corn cycle. It was −0.55% on a trailing basis by mid-2026 (S&P).

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Segment Overview

SegmentContentsProducts

Upstream products

Manufacture and sale of cornstarch and ancillary corn-refined products

Native cornstarch, corn gluten meal, corn germ, corn fibre/bran, corn steep liquor (slurry)

Fermented and downstream products

Manufacture and sale of lysine, starch-based sweetener, modified starch and other products

Lysine (several purity grades), liquid and crystallised starch sweeteners, modified starch (incl. liquid modified starch), biobased materials (lactic acid and related), other fermented products

Revenue by Segment

SegmentFY2021FY2022FY2023FY2024FY2025

Upstream products revenue (CNY Mn)

8,576.58,706.08,596.97,007.96,313.4

Fermented and downstream revenue (CNY Mn)

3,062.83,242.93,200.74,407.93,745.1

Total revenue (CNY Mn)

11,639.311,948.911,797.511,415.810,058.5

Inter-segment sales, upstream (CNY Mn)

220.11,485.91,603.72,249.32,006.0

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Results by Segment and Segment Margins & Growth (%)

MetricFY2021FY2022FY2023FY2024FY2025

Upstream gross profit (CNY Mn)

496.4441.7130.0429.3172.5

Fermented and downstream gross profit (CNY Mn)

455.9748.8426.6733.9368.4

Upstream reportable segment profit (CNY Mn)

443.0230.2-85.4233.910.9

Fermented and downstream segment profit (CNY Mn)

333.1396.7263.4582.7241.9

Upstream gross margin (%)

5.85.11.56.12.7

Fermented and downstream gross margin (%)

14.923.113.316.79.8

Segment Margins & Growth (%) and Revenue by Segment (%)

MetricFY2022FY2023FY2024FY2025

Upstream revenue growth YoY (%)

1.5-1.3-18.5-9.9

Fermented and downstream revenue growth YoY (%)

5.9-1.337.7-15.0

Upstream share of revenue (%)

72.972.961.462.8

Fermented and downstream share of revenue (%)

27.127.138.637.2

Products

ProductFY2021FY2022FY2023FY2024FY2025

Lysine (CNY Mn)

2,224.22,424.72,261.83,427.62,922.9

Starch-based sweetener (CNY Mn)

519.5541.4472.2500.6444.0

Modified starch (CNY Mn)

267.5196.0351.6374.6211.7

Others incl. biobased materials (CNY Mn)

51.680.8115.1105.1166.6

Results by Segment and Segment Margins & Growth (%) (Half-Yearly)

MetricH1 2025H1 2026

Upstream revenue (CNY Mn)

3,149.73,191.4

Upstream gross profit (CNY Mn)

91.578.7

Upstream gross margin (%)

2.92.5

Upstream segment result (CNY Mn)

5.6-32.3

Fermented and downstream revenue (CNY Mn)

1,965.11,831.0

Fermented and downstream gross profit (CNY Mn)

337.355.0

Fermented and downstream gross margin (%)

17.23.0

Fermented and downstream segment result (CNY Mn)

295.19.2

Income Statement and Per-Share Data

MetricFY2021FY2022FY2023FY2024FY2025

Revenue (CNY Mn)

11,639.311,948.911,797.511,415.810,058.5

Cost of sales (CNY Mn)

10,687.110,758.411,241.010,252.59,517.5

Gross profit (CNY Mn)

952.21,190.5556.61,163.2540.9

Distribution expenses (CNY Mn)

164.9171.0157.2157.9124.3

Administrative expenses (CNY Mn)

192.0207.8194.6217.3227.7

Research expenses (CNY Mn)

199.6324.1160.589.746.8

Other net income (CNY Mn)

114.9119.8113.1117.6121.6

Operating profit (CNY Mn)

510.5607.3157.5815.9263.9

D&A (CNY Mn)

259.3284.8277.4285.5276.2

EBITDA, derived (CNY Mn)

769.8892.1434.81,101.4540.0

Finance income (CNY Mn)

8.118.324.131.049.3

Finance expenses (CNY Mn)

7.14.54.88.811.2

Profit before tax (CNY Mn)

511.5621.1176.8838.1302.0

Income tax (CNY Mn)

108.7125.719.4212.664.6

Profit for the year (CNY Mn)

402.8495.4157.4625.6237.4

Profit attributable to owners (CNY Mn)

345.6352.0108.0482.3184.9

Non-controlling interests (CNY Mn)

57.2143.449.4143.352.4

Basic EPS (MYR Bn)

0.05770.05870.01800.08080.0310

Diluted EPS (MYR Bn)

0.05770.05870.01800.08080.0310

Final DPS (HK cents)

0.690.690.690.980.98

Margin Analysis (%)

MetricFY2021FY2022FY2023FY2024FY2025

Revenue growth YoY (%)

30.92.7-1.3-3.2-11.9

Gross margin (%)

8.210.04.710.25.4

Operating margin (%)

4.45.11.37.12.6

EBITDA margin (%)

6.67.53.79.65.4

Net margin, attributable (%)

3.02.90.94.21.8

Effective tax rate (%)

21.220.211.025.421.4

Balance Sheet

MetricFY2021FY2022FY2023FY2024FY2025

Total assets (CNY Mn)

4,719.25,105.85,352.66,958.96,822.8

Property, plant and equipment (CNY Mn)

2,004.31,892.12,162.52,014.02,046.6

Right-of-use assets (CNY Mn)

447.2436.3425.9415.6418.0

Intangible assets incl. goodwill (CNY Mn)

000075.5

Inventories (CNY Mn)

602.3866.4730.7611.1772.0

Cash and cash equivalents (CNY Mn)

1,001.01,003.0899.82,209.91,858.6

Pledged bank deposits (CNY Mn)

0207.6500.11,160.1995.6

Short-term borrowings (CNY Mn)

108.2285.9559.41,420.31,020.0

Long-term borrowings (CNY Mn)

3.00059.360.5

Total borrowings (CNY Mn)

111.2285.9559.41,479.61,080.5

Net debt, excl. pledged deposits (CNY Mn; negative = net cash)

-889.8-717.1-340.5-730.3-778.0

Net debt, incl. pledged deposits (CNY Mn)

-889.8-924.7-840.5-1,890.4-1,773.7

Equity attributable to owners (CNY Mn)

3,278.03,595.13,661.84,106.04,237.6

Total equity (CNY Mn)

3,492.03,821.83,936.64,493.74,650.7

Current assets (CNY Mn)

2,197.62,666.52,697.64,419.44,135.9

Current liabilities (CNY Mn)

894.2965.91,192.42,158.61,928.8

Working capital (CNY Mn)

1,303.51,700.61,505.32,260.82,207.2

Cash Flow

MetricFY2021FY2022FY2023FY2024FY2025

Operating cash flow (CNY Mn)

1,107.0316.8413.41,317.0298.9

Capital expenditure (CNY Mn)

394.9211.1421.6255.0338.2

Free cash flow (CNY Mn)

712.0105.7-8.31,062.0-39.3

Dividends paid (CNY Mn)

44.9138.466.967.980.3

Share buybacks (CNY Mn)

003.10.60

Net debt issued / (repaid) (CNY Mn)

-15.5172.9273.4919.0-397.6

Change in working capital (CNY Mn)

446.1-344.167.6356.2-96.2

Margin Analysis (%) and Financial Ratios (x)

RatioFY2021FY2022FY2023FY2024FY2025

ROE, attributable, avg equity (%)

10.510.23.012.44.4

ROA, profit for year / avg assets (%)

8.510.13.010.23.4

ROIC, derived (%)

14.714.73.316.35.1

Current ratio (x)

2.52.82.32.02.1

Quick ratio (x)

1.81.91.61.81.7

Gearing, borrowings / total assets (%)

2.45.610.521.315.8

Debt / equity (%)

3.27.514.232.923.2

Net debt / EBITDA (x)

-1.16-0.80-0.78-0.66-1.44

Interest coverage, operating profit / finance expense (x)

71.9135.833.192.323.6

Asset turnover (x)

2.472.432.261.851.46

Debtor days

1411121213

Inventory days

2425262427

Creditor days

775510

Cash conversion cycle (days)

3129333130

Total shareholder return, company-reported (%)

41.79.4-36.544.8-0.1

Revenue by Region and Revenue by Region (%)

RegionFY2021FY2022FY2023FY2024FY2025

PRC revenue (CNY Mn)

10,811.011,493.610,856.910,702.59,609.7

Other countries revenue (CNY Mn)

828.4455.3940.6713.2448.8

Overseas share of revenue (%)

7.13.88.06.24.5

Region Margins & Growth (%)

RegionFY2022FY2023FY2024FY2025

PRC growth YoY (%)

6.3-5.5-1.4-10.2

Other countries growth YoY (%)

-45.0106.6-24.2-37.1

Valuation Snapshot

MetricValue

Share price (HKD)

0.176

Market capitalisation (HKD Bn)

1.03

Enterprise value (HKD Bn)

0.67

52-week change (%)

-12.87

Beta (5Y)

0.39

Average daily volume (20-day, shares)

4,966,843

Trailing P/E (x)

48.4

P/B (x)

0.20

P/TBV (x)

0.22

EV/Sales (x)

0.06

EV/EBITDA, TTM (x)

3.30

Dividend yield (%)

6.0

Net cash (HKD Mn)

798.6

Altman Z-score / Piotroski F-score

2.5 / 1

Margin Analysis (%) — Total shareholder return

MetricFY2021FY2022FY2023FY2024FY2025

Total shareholder return (%)

41.79.4-36.544.8-0.1

Capital Markets

MetricChina StarchFufeng Group

FY2025 net margin (%)

1.88.8

FY2025 gross margin (%)

5.419.7

P/B (x)

0.20—

Per-Share Data

MetricFY2020FY2021FY2022FY2023FY2024FY2025

Final DPS (HK cents)

0.900.690.690.690.980.98

Interim DPS (HK cents)

000000

Returns & Leverage Ratios (%)

MetricFY2021FY2022FY2023FY2024FY2025

Payout ratio, final dividend / attributable profit (%, derived)

1011351129

Share Price & Returns

PeriodShares repurchased (M)Consideration (HKD Mn)Price range (HKD)

Aug–Dec 2023

25.5653.375

0.127–0.145

FY2025

00—

H1 2026

104.46517.569

0.146–0.19

1–17 Jul 2026

49.5358.389

0.155–0.178

Analyst Conclusions

Management guidance (H1 2026 Interim Results)

  • No numerical guidance.

  • Management expects H2 2026 to remain challenging, with no clear signs of a near-term recovery.

  • Priorities: efficiency, cost control and cautious capital allocation that avoids capacity-glut products.

  • Linqing trial operation by end-2026; thermal plant Q1 2027.

Consensus

Simply Wall St indicates 4 analysts cover the stock (May 2025). Their estimates and price targets are not publicly disclosed in the sources retrieved. Consensus growth expectations are n/d.

Bull case

  1. Valuation floor. The stock trades at about 0.20x book (equity RMB4.16bn at 30 Jun 2026) with net cash including pledged deposits of about RMB1.18bn at H1 2026. Enterprise value of HK$0.67bn is about 3.3x trailing EBITDA. Mid-cycle profit like FY2022 (RMB352m) or FY2024 (RMB482m) would imply a very low multiple.

  2. Cost-curve step-down from 2027. The rebuilt 1.55Mt Linqing line plus captive power targets the two biggest cost items, corn yield and utilities (RMB1.0bn a year). That could lift upstream margins above the 1.5%–6.1% historical range.

  3. Cycle mean reversion plus consolidation. Lysine ASP (RMB4,607/t) is 40% below its FY2022 peak. Exits by weaker players and a hog-cycle upturn have historically produced sharp rebounds (FY2024 gross profit +109%). Ongoing buybacks amplify per-share recovery.

Bear case

  1. Structural loss of export outlets. EU duties of 47.7%–58.3% and U.S. AD deposits of 142.59% keep Chinese lysine at home, entrenching domestic oversupply. China Starch has no differentiated amino acids to pivot to, unlike Meihua and Fufeng.

  2. Earnings quality erodes. Grant amortisation (RMB60–80m a year) has largely ended, R&D has been cut to 0.47% of revenue, and the corn exposure is unhedged. Without a spread recovery, FY2026 could be the first full-year loss in the review period: H1 2026 already shows an attributable loss of RMB14.7m.

  3. Capital allocation and governance discount. RMB1.05bn of capex is going into commoditised cornstarch, which management itself calls oversupplied. Execution runs through connected-party contractors. With about 64% control, minority shareholders have little influence and the discount to book may persist.

Catalysts and monitorables (next 12 months)

ItemTiming
Linqing new cornstarch line trial operationEnd-2026
Thermal power plant commissioningQ1 2027
FY2026 profit warning / alert, if anyFeb 2027 (historical pattern)
FY2026 annual results and final dividend decisionMar 2027
EU lysine absorption investigation outcome (possible duty increase)H2 2026 – 2027
U.S. ITC final injury determination / AD-CVD orders on L-lysineH2 2026
Corn kernel price trajectory (state reserve buying, import policy)Ongoing
PRC hog inventory and feed demandOngoing
Musashino JV go / no-go decisionPending
Further buybacks under the AGM mandateOngoing

Analyst verdict

China Starch Holdings is a well-capitalised but structurally low-return corn processor sitting at the bottom of a cyclical trough.

The five-year record shows the business as it is: revenue drifting from RMB11.6bn to RMB10.1bn and gross margins swinging between 4.7% and 10.2% with the corn spread. Attributable profit has ranged from RMB108m to RMB482m with no visible structural uplift. The FY2024 peak came from cheap corn plus new lysine scale. It reversed within eighteen months as corn costs rose and export markets closed behind anti-dumping walls in the EU and U.S. By H1 2026, lysine gross margin had fallen from 17.2% to 3.0% and the group recorded an interim loss.

Against this, the balance sheet is unusually strong for the sector. Cash and pledged deposits exceed borrowings by about RMB1.2bn, book equity is about RMB4.2bn, and the market values the whole company at about HK$1.0bn. Management is using that strength to rebuild Linqing at larger scale with captive power, and to retire shares at about a fifth of book value. Both actions make sense in a consolidating industry where survivors with cost advantages should gain share.

The key unknowns are timing and returns. Commissioning at end-2026 and Q1 2027 means cost benefits will not show until FY2027 results. Grant income has rolled off. Domestic oversupply is being worsened by trade diversion that China Starch cannot control. The company also lacks the higher-value amino acid portfolio that protects larger peers such as Fufeng (19.7% gross margin in FY2025).

Verdict: The stock offers deep value and optionality on a corn and lysine recovery, backed by downside protection from net cash and a stable final dividend. It is not a compounding franchise. Investors should treat it as a cyclical, book-value-anchored position, monitor the Linqing ramp-up and FY2026 dividend decision closely, and size it with the governance and trade-policy discounts in mind.


Data limitations: - Peer figures are limited to verified disclosures.

  • All derived metrics are labelled as such.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Board of Directors

NameRoleTenure / appointmentAge / birth yearBackground (as disclosed)

Tian Qixiang

Executive Chairman

Chairman since listing (named in the 2007 Annual Report)

Born 1964 (Yahoo)

Founder-chairman. Did not attend the 2022–2026 AGMs, a recurring Corporate Governance Code deviation. Further profile in AR2025 (pp.

Gao Shijun

CEO and Executive Director

CEO since 7 Dec 2009 (MarketScreener; another source says 2011)

Born 1968

Undergraduate, Shandong University (1989); MBA, Shandong University (2012). Director and GM of Golden Corn; director of DGC, Golden Far East Modified Starch, Golden Corn Biotechnology and the Musashino JV. Former member, China Starch Industry Association.

Yu Yingquan

Executive Director

—

Born 1969

—

Liu Xianggang

Executive Director

—

Born 1969

—

Prof. Chen Zhijun

INED

Appointed 15 Oct 2025

—

n/d in sources retrieved

Prof. Gao Qunyu

INED; Chair of Remuneration Committee; member of Audit and Nomination Committees

Effective from 12 May 2026 AGM, 3-year term; fee RMB50,000 a year

60

Professor and doctoral supervisor, South China University of Technology (since 2008). BSc, MSc and PhD in sugar engineering (SCUT). Vice Chairman, China Starch Industry Association. Deputy Director, National Technical Committee for Standardization of Edible Starch and Starch Derivatives. Editorial board of Carbohydrate Polymers.

Ms. Sze Tak On

INED

n/d (on the board by FY2025)

——

Leung Siu Hong

Company Secretary

—

Born 1976

FCCA, FCIS, FCPA, FCS

Board & Management Changes

DateChange

Between 20 Mar 2024 and early 2025

Mr. Yue Kwai Wa, Ken ceased to be an INED. Exact date n/d; Ms. Sze Tak On appears to be his successor.

15 Oct 2025

Mr. Sun Mingdao retired as INED; Prof. Chen Zhijun appointed

12 May 2026

Prof. Hua Qiang retired after 9 years as INED (previously Remuneration Committee Chair); Prof. Gao Qunyu appointed

Directors' Remuneration

ExecutiveTotal pay FY2023 (USD K)

Tian Qixiang

66.16

Gao Shijun

75.40

Yu Yingquan

56.52

Liu Xianggang

56.52

Major Shareholders

HolderShares (M)Stake (%)Source / date

Merry Boom Group Limited (controlling shareholder)

3,705.462.1

Simply Wall St, May 2025 (on 5,964.5m shares)

Merry Boom Group Limited, pro forma

3,705.463.8

Derived on about 5,810.5m shares after Aug 2026 cancellation

Dimensional Fund Advisors LP

33.00.55

Simply Wall St, May 2025

Tareno International Asset Managers

13.70.23

Simply Wall St

Polunin Capital Partners

3.30.06

Simply Wall St

Acadian Asset Management

2.60.04

Simply Wall St

American Century Investment Management

1.90.03

Simply Wall St

Primorski Skladi

1.40.02

Simply Wall St

Total institutions

55.90.94

Simply Wall St

General public

2,203.236.9

Simply Wall St

Competitive Landscape

Competitors by Segment

SegmentCompetitorListingPositioning vs China Starch

Lysine / amino acids

Meihua Holdings Group

600873.SS

Global leader in MSG and lysine; 2025 revenue RMB24.21bn; bought Kyowa Hakko's amino acid business in 2025; lowest EU duty (47.7%)

Lysine / amino acids

Fufeng Group

0546.HK

2025 revenue RMB27.88bn; lysine volume 435,140t (+30.4%); gross margin 19.7%

Lysine / amino acids

Inner Mongolia Eppen Biotech

Private

Large lysine exporter; EU duty 58.2%; received an individual U.S. rate

Lysine / amino acids

CJ CheilJedang (Bio)

097950.KS

Global lysine leader; U.S. AD petitioner via CJ Bio America

Lysine / amino acids

Archer Daniels Midland

ADM (NYSE)

U.S. lysine producer; AD petitioner

Lysine / amino acids

Eurolysine (Avril Group)

Private

Sole EU lysine producer; EU AD complainant

Cornstarch / sweeteners

COFCO Biotechnology

000930.SZ

State-backed corn processing and fuel ethanol

Cornstarch / sweeteners

Global Bio-chem Technology / Global Sweeteners

0809.HK / 3889.HK

Northeast China corn refiners; much reduced scale

Cornstarch / co-products

Jinhe Biotechnology

002688.SZ

Starch and co-products alongside feed antibiotics

Cornstarch / co-products

Shandong Ensign Industry

300183.SZ (verify)

Shandong cornstarch producer; listed by CNChemicals as a peer

Cornstarch / co-products

Zhucheng Xingmao Corn Developing

Private

Large Shandong cornstarch and sweetener producer

Global starch

Cargill, Ingredion, Roquette, Tate & Lyle

Various

Global specialty starch leaders; limited direct PRC commodity overlap

Peer Comparison FY2025

MetricChina StarchFufeng GroupMeihua Holdings

Revenue FY2025 (CNY Mn)

10,058.527,87924,209

Revenue growth FY2025 (%)

-11.90.4-3.4

Gross margin FY2025 (%)

5.419.7—

Net margin FY2025 (%)

1.88.813.6

Net profit FY2025 (CNY Mn)

184.92,4653,281

R&D % of revenue

0.47——

Recent Developments

--

Company Snapshot

$1,399M

Revenue

2,177

Employees

2006

Founded

P.O. Box, Cayman Islands

Headquarters

SWOT Analysis

Strengths

  • Net-cash balance sheet. Cash RMB1,858.6m plus pledged deposits RMB995.6m against borrowings of RMB1,080.5m at FY2025 (net cash about RMB1.77bn including pledged deposits).
  • Integrated value chain. RMB2,006m of upstream starch was transferred internally in FY2025, giving captive feedstock for fermentation.
  • Lean cost base. Distribution plus admin was 3.5% of revenue in FY2025 (RMB352m); debtor days 13 and inventory days 27.
  • Lysine scale. 500kt capacity (end-2023); volume 561kt in FY2025, about 70% higher than FY2023.
  • Consistent dividends. A final dividend was paid every year FY2020–FY2025 (HK0.69–0.98 cents), held at HK0.98 cents in FY2025 despite a 62% profit fall.
  • HNTE tax benefit. 15% preferential EIT at one subsidiary; withholding tax on PRC dividends cut to 5% (from 10%) after HK tax residency was recognised (FY2025).

Weaknesses

  • Thin margins. Upstream gross margin of 1.5%–6.1% over FY2021–FY2025; group gross margin 2.7% in H1 2026.
  • No corn hedging. No forward or futures hedging in any period FY2021–H1 2026.
  • R&D collapse. Spend down 86% to RMB46.8m (0.47% of revenue) in FY2025.
  • Earnings depend on non-operating support. Government-grant amortisation was RMB66–82m a year in FY2021–FY2025 and fell to RMB6.7m in H1 2026.
  • Modified starch capacity is regulation-bound. Volume fell 43% in FY2025 (113kt to 65kt) on sewage controls.
  • Governance. Executive-heavy board (4 of 7); chairman absent from AGMs every year; repeated connected-party construction contracts (RMB150m).

Opportunities

  • Linqing rebuild. +550kt cornstarch capacity at Linqing (+55%), expected to lower unit cost, with trial operation by end-2026.
  • Captive thermal power from Q1 2027, cutting utility cost (RMB1,012m in FY2025, about 11% of cost of sales).
  • Industry consolidation. Management expects laggards to lose share; China Starch has the balance sheet to survive the trough.
  • Hog-cycle recovery would lift lysine and corn gluten meal demand. FY2022 lysine ASP was RMB7,718/t, against RMB4,607/t in H1 2026.
  • Buybacks below book value (P/B about 0.20x) are accretive. 154m shares were retired in 2026.
  • Biobased materials. Revenue rose from RMB51.6m (FY2021) to RMB166.6m (FY2025), and volume grew again in H1 2026.

Threats

  • EU anti-dumping. Definitive duties of 47.7%–58.3% from 12 Jul 2025; imports placed under registration on 28 Jul 2026 (Reg. 2026/1824), raising the risk of retroactive duties.
  • U.S. AD/CVD on L-lysine. Preliminary China-wide AD cash deposit of 142.59% from 6 Mar 2026; final determinations mid-2026.
  • Domestic oversupply in cornstarch, lysine and sweeteners. Management cites it in every period FY2023–H1 2026.
  • Corn cost inflation from state reserve buying and import curbs. H1 2026 corn was RMB2,175/t vs RMB2,068/t.
  • Substitute starches. Tapioca and wheat starch took share in 2025 (FY2025 MD&A).
  • Freight and geopolitics. Middle East disruption raised export freight in 2026 (profit warning, 22 Jun 2026).

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
10 Apr 2025Annual Report 2024 published; it includes an Environmental and Sustainability ReportLast AR to embed the ESG report; the AR2025 ESG report is standalone
25 May 2025DGC signs RMB80m construction contract with Juneng ConstructionStarts execution of the Linqing rebuild; connected party
H1 2025One Linqing cornstarch line demolishedCapacity and volume drag through 2026
12 Jul 2025EU definitive anti-dumping duties on Chinese lysine take effect (5 years)Structural loss of EU export access; diverted volume deflates the domestic price
20 Aug 2025H1 2025 results: revenue −9.4% to RMB5.11bn; attributable profit −29.5% to RMB151.4m; no interim dividendFirst sign of the margin downturn
Aug 2025Nomination Committee terms of reference updatedGovernance housekeeping
18 Sep 2025Circular and independent financial adviser (Central China International Capital) on the construction contractMinority-protection process
9 Oct 2025EGM approves the construction contract (99.99%)Clears the path for the Linqing project
15 Oct 2025Prof. Chen Zhijun appointed INED; Sun Mingdao retiresBoard refresh
19 Nov 2025RMB70m thermal plant construction contract (connected transaction)Energy self-supply project
22 Jan 2026U.S. Commerce preliminary affirmative CVD determination on L-lysine from China (published)Escalating U.S. trade barrier
30 Jan 2026 (planned)Thermal plant construction startCapex ramp
Feb 2026JV acquires 65,642 m² land for RMB23.64mJV milestone, later put under appraisal
23 Feb 2026FY2025 profit warningCorn up three quarters in a row; lysine oversupply; anti-dumping
6 Mar 2026U.S. preliminary AD: China-wide cash deposit 142.59%; CBP suspends liquidationEffectively closes the U.S. market for non-rated exporters
6 Mar 2026Board meeting notice for resultsRoutine
18 Mar 2026FY2025 results: revenue RMB10.06bn (−11.9%); attributable profit RMB184.9m (−61.7%); final dividend HK0.98 cents heldDividend held despite the profit drop
13 Apr 2026Annual Report 2025 publishedPrimary reference
12 May 2026AGM; Prof. Gao Qunyu appointed and Prof. Hua Qiang retires; chairman absentIndustry-expert INED added
19 May 2026Ex-dividend date for FY2025 final dividendPaid about 11 Jun 2026
H1 2026Repurchase of 104.465m shares at HK$0.146–0.19 (HK$17.569m)Capital return at about 0.2x P/B
22 Jun 2026Profit warning: loss before tax for the five months to 31 May 2026 (vs about RMB267m profit a year earlier); freight costs citedEarly signal of the H1 loss
June–July 2026U.S. final affirmative AD and CVD determinations on L-lysine from China (Federal Register public inspection)–
1–17 Jul 2026Further repurchase of 49.535m shares (HK$8.389m)Total 154m shares bought back
28 Jul 2026EU Implementing Reg. 2026/1824 makes Chinese lysine imports subject to registration after an absorption investigationPossible retroactive higher duties; further pressure on EU-bound volume
3 Aug 2026154m repurchased shares cancelledAbout 2.6% share count reduction
7 Aug 2026Board meeting notice for interim resultsConfirms board composition
19 Aug 2026H1 2026 results: revenue RMB5.02bn (−1.8%); gross profit −68.8%; attributable loss RMB14.7m; no interim dividend; JV under reappraisalFirst interim loss in the review period
about 11 Sep 2026Interim Report 2026 publishedPrimary reference

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

7 charts
Income Statement: Revenue & Gross Profit: Revenue fell from CNY 11,639.3 Mn in FY2021 to CNY 10,058.5 Mn in FY2025.
China Starch Holdings Limited — Income Statement: Revenue & Gross Profit
Series (CNY Mn)FY2021FY2022FY2023FY2024FY2025
Revenue11,639.311,948.911,797.511,415.810,058.5
Cost of sales10,687.110,758.411,24110,252.59,517.5
Gross profit952.21,190.5556.61,163.2540.9

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.